Mediators of Inflammation / 2018 / Article / Tab 4

Research Article

Neostigmine Attenuates Proinflammatory Cytokine Expression in Preoptic Area but Not Choroid Plexus during Lipopolysaccharide-Induced Systemic Inflammation

Table 4

Effect of lipopolysaccharide (LPS; 400 ng/kg; iv.) and acetylcholinesterase inhibitors: donepezil (2.5 mg/animal; iv.) and neostigmine (0.5 mg/animal; iv.) injections on the relative gene expression (mean ± SEM; animals per group) of proinflammatory cytokines and their corresponding receptors in the ovine choroid plexus.

GeneChoroid plexus
ControlDon.Neo.LPSDon. + LPSNeo. + LPS

IL-1β1 ± 0.2A0.6 ± 0.1A0.5 ± 0.1A4.3 ± 1.5B4 ± 0.7B5.7 ± 1.4B
IL1R11 ± 0.2A0.8 ± 0.1A0.9 ± 0.1A2.1 ± 0.5B2.2 ± 0.3B2.1 ± 0.2B
IL1R21 ± 0.2A0.6 ± 0.1A1.1 ± 0.3A2.9 ± 0.7B3.7 ± 0.7B4.4 ± 0.9B
IL-1RA1 ± 0.1A1 ± 0.1A1.3 ± 0.1A9.4 ± 0.6B12.4 ± 1.3B12.7 ± 2.5B
IL-61 ± 0.4A0.9 ± 0.1A1.2 ± 0.3A84 ± 27B84 ± 9B123 ± 40B
IL6R1 ± 0.1AC1 ± 0.1A1.1 ± 0.0A0.8 ± 0.1BC0.9 ± 0.1ABC0.7 ± 0.1B
IL6ST1 ± 0.2A0.7 ± 0.1A0.9 ± 0.1A1.7 ± 0.2B2 ± 0.2B1.8 ± 0.4B
TNF1 ± 0.1A0.7 ± 0.1A1 ± 0.1A1.9 ± 0.6B1.6 ± 0.2B1.9 ± 06B
TNFRSF1A1 ± 0.1A0.8 ± 0.1A1 ± 0.1A1.3 ± 0.1B1.4 ± 0.1B1.4 ± 0.1B
TNFRSF1B1 ± 0.1AB0.8 ± 0.1A0.8 ± 0.1A1.6 ± 0.3C1.7 ± 0.3C1.4 ± 0.2BC

IL-1β: interleukin-1β; IL1R1 and IL1R2: interleukin receptor types 1 and 2; IL1RN: interleukin-1 receptor antagonist; IL-6: interleukin-6; IL6R: glycoprotein 130; TNF: tumor necrosis factor; TNFRSF1A and B: tumor necrosis factor receptor types 1 and 2; TLR4: toll-like receptor 4. The gene expression data were normalised to the average relative level of gene expression in the control group of ewes, which was set to 1.0. Different capital letters indicate significant () differences according to a two-way ANOVA followed by Fisher’s post hoc test.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.